Main Antibiotic Classes
The major antibiotic classes used in clinical practice include β-lactams (penicillins, cephalosporins, carbapenems), macrolides, fluoroquinolones, tetracyclines, aminoglycosides, glycopeptides, oxazolidinones, and several others, each with distinct mechanisms of action and clinical applications 1, 2.
Core Antibiotic Classes by Mechanism of Action
Cell Wall Synthesis Inhibitors
β-Lactams are the most widely used antibiotic class, encompassing:
- Penicillins (amoxicillin, ampicillin, piperacillin)
- Cephalosporins (cefazolin, ceftriaxone, cefotaxime, ceftazidime)
- Carbapenems (meropenem, imipenem, ertapenem)
- β-lactam/β-lactamase inhibitor combinations (amoxicillin-clavulanic acid, piperacillin-tazobactam, ampicillin-sulbactam)
These agents inhibit peptidoglycan synthesis in bacterial cell walls 2. The guidelines consistently recommend β-lactams as first-line therapy across multiple infection types 3.
Glycopeptides (vancomycin) also target cell wall synthesis and are reserved primarily for MRSA infections 3, 2.
Protein Synthesis Inhibitors
Multiple classes target bacterial ribosomes at different sites:
Macrolides (clarithromycin, azithromycin, erythromycin) bind the 50S ribosomal subunit 2. Guidelines recommend clarithromycin over erythromycin due to fewer adverse events, and caution against azithromycin due to cardiovascular risks 3.
Aminoglycosides (gentamicin, tobramycin) target the 30S ribosomal subunit 2. They are frequently used in combination therapy for severe infections 3.
Tetracyclines (doxycycline) inhibit protein synthesis and have broad applications 2, 3.
Oxazolidinones (linezolid) represent a newer class for Gram-positive infections, particularly MRSA 3, 2.
Lincosamides (clindamycin) and streptogramins also inhibit protein synthesis 2.
Nucleic Acid Synthesis Inhibitors
Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) inhibit DNA gyrase and topoisomerase IV 2. Guidelines classify these as "Watch" category antibiotics due to resistance concerns and significant adverse effects involving tendons, muscles, joints, nerves, and the central nervous system 3.
Rifamycins target RNA polymerase 2.
Metabolic Pathway Inhibitors
Sulfonamides and trimethoprim (sulfamethoxazole-trimethoprim) interfere with folate biosynthesis 2.
Nitroimidazoles (metronidazole) provide anaerobic coverage and are frequently combined with other agents 3.
WHO AWaRe Classification Framework
The 2024 WHO guidelines organize antibiotics into three stewardship categories 3:
- Access (A): First-line agents with lower resistance potential (amoxicillin, ampicillin, gentamicin, metronidazole)
- Watch (W): Second-line agents requiring monitoring (ceftriaxone, cefotaxime, ciprofloxacin, levofloxacin, piperacillin-tazobactam, meropenem, vancomycin)
- Reserve: Last-resort agents for multidrug-resistant organisms
Clinical Application Patterns
Guidelines demonstrate consistent patterns across infection types 3:
For mild-moderate infections: Narrow-spectrum β-lactams or β-lactam/β-lactamase inhibitor combinations serve as first-line therapy.
For severe infections: Broader-spectrum cephalosporins (ceftriaxone, cefotaxime) or β-lactam/β-lactamase inhibitor combinations (piperacillin-tazobactam), often with additional coverage.
For MRSA: Vancomycin or linezolid are the primary options 3.
For Pseudomonas aeruginosa: Antipseudomonal β-lactams (piperacillin-tazobactam, ceftazidime, cefepime), carbapenems, or fluoroquinolones 3.
Critical Considerations
Resistance is the defining challenge across all antibiotic classes 1, 4, 5, 6. The extensive use of antibiotics has progressively reduced their efficacy, with relatively few new agents in development 4, 5, 7.
Class-specific toxicities must guide selection: fluoroquinolones carry musculoskeletal and neurological risks 3, aminoglycosides require monitoring for nephrotoxicity and ototoxicity, and macrolides have cardiovascular concerns 3.
Combination therapy is frequently necessary for severe infections, particularly to provide anaerobic coverage (adding metronidazole) or to cover resistant organisms 3.